Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

AB Adams PC

Neither a doctor nor a teaching hospital

Research payments

$4,662,951

319 payments

Through program year 2025, AB Adams PC is reported as receiving $4,662,951 in research payments, across 319 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $106,267 5
2024 Research $257,781 4
2023 Research $527,316 12
2022 Research $1,437,815 166
2021 Research $2,263,525 108
2020 Research $41,194 14
2019 Research $29,053 10

Breakdown

Who paid Research payments · program years 2019–2025
  1. Moderna TX, Inc. $4,083,850 263 payments
  2. Novartis Pharmaceuticals Corporation $406,066 9 payments
  3. Gilead Sciences, Inc. $57,533 8 payments
  4. AbbVie, Inc. $38,179 12 payments
  5. AstraZeneca Pharmaceuticals LP $25,415 6 payments
  6. Bayer HealthCare Pharmaceuticals Inc. $23,367 17 payments
  7. Sanofi US Services Inc. $19,756 2 payments
  8. Regeneron Pharmaceuticals, Inc. $7,500 1 payment
  9. Sanofi Pasteur Inc. $1,287 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older $4,083,850 263 payments
  2. A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) $205,100 3 payments
  3. A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) in US Black/African American & Hispanic patient populations with elevated Lp(a) and established atherosclerotic cardiovascular disease $90,905 1 payment
  4. Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (Victorion-2 Prevent) $65,461 3 payments
  5. A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men $36,433 10 payments
  6. A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) in US Black/African American & Hispanic patient populations with elevated Lp(a) and established atherosclerotic cardi $34,099 1 payment
  7. A Multicentre, Double-blind, Randomized, Placebo Controlled, Parallel Group, Phase 3, Safety Extension Study to Evaluate the Safety and Tolerability of Tezepelumab in Adults and Adolescents with Severe Uncontrolled Asthma. $25,415 6 payments
  8. A Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multicenter study, to investigate the efficacy and safety of lunsekimig in adult participants with inadequately controlled chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype $18,756 1 payment
  9. BAY94-8862 ph 3 conventional in diabetic nephropathy $17,888 15 payments
  10. Phase 3 Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734) treatment of COVID-19 in an outpatient setting $17,475 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record